Ranbaxy settle case with Cephalon
Facebook Twitter google+ RSS Feed

Ranbaxy settle case with Cephalon

By agencies   |   Friday, 23 December 2005, 08:00 Hrs
Printer Print Email Email
NEW DELHI: Close on the heels of a U.S. district court ruling against its patent challenge of Pfizer's Lipitor, Ranbaxy Laboratories Ltd Friday said it had entered into an out of court settlement with Cephalon Inc for the patent infringement dispute in the U.S. related to psychostimulant Provigil (modafinil) tablets.

As per the settlement, Cephalon will grant the Ranbaxy a non-exclusive royalty-bearing right to market and sell a generic version of Provigil in the U.S., a company statement said.

The company's license will become effective in October 2011 in the absence of a pediatric extension for Provigil, which would delay the entry date by six months (to April, 2012), it added.

Ranbaxy said that an earlier entry might occur based upon the entry of another generic version of Provigil.

The two companies have agreed to a series of business arrangements related to modafinil.
Ranbaxy has agreed to grant to Cephalon an immediate non-exclusive license to certain of its worldwide intellectual property rights related to modafinil in exchange for milestone payments. Cephalon also has agreed to enter into certain arrangements with Ranbaxy regarding supply of the active pharmaceutical ingredient modafinil, it added.

The two parties would promptly file for dismissal of their litigation in the U.S. District Court of New Jersey, it said, adding, however, the out of court settlement would be subject to the approval of U.S. Federal Trade Commission.

Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Sr. Executive
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
Reena Khanna
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset